Astrana Health, Inc.
NASDAQ:ASTH · NASDAQ Capital Market
+$1.03 today
Vol 0.83M · Avg 0.51M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
2.9%
avg -9.6%
ROIC
2.9%
avg 0.5%
ROA
1.0%
avg -1.8%
Analysis
ROE is currently the strongest return metric at 2.9% versus its period average of -9.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Brandon Sim | President & Chief Executive Officer | $2.93M | — | 32 | $739,407.00 | 1.49% |
Dinesh Kumar | Chief Medical Officer | $2.08M | — | 57 | $235,635.00 | 0.48% |
Chandan Basho | Chief Financial Officer, Chief Operating Officer & Corporate Secretary | $1.67M | — | 43 | $159,610.00 | 0.32% |
Kenneth T. Sim | Co-Founder & Executive Chairman | $1.07M | — | 71 | $739,407.00 | 1.49% |
Thomas S. Lam | Co-Founder & Vice Chairman | $985,530.00 | — | 77 | $465,657.00 | 0.94% |
WaiChow Young | Senior Vice President of Health Affairs | $452,281.00 | — | 78 | — | — |
Boon Chen | Senior Vice President of Engineering | — | — | — | — | — |
Paul Van Duine | Senior Vice President of Contracting | — | — | — | — | — |
Jeremy R. Jackson | Chief Quality Officer | — | — | — | — | — |
Jaime Melkonoff | President of AstranaCare - Texas | — | — | — | — | — |
Rita Pew | Chief People Officer | — | — | — | — | — |
Glenn W. Sobotka | Chief Accounting Officer & Principal Accounting Officer | — | — | 48 | $14,039.00 | 0.03% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +3.9% | +13.5% (10yr)1 analysts |
| Revenue | N/A | N/A | +1.2% | +30.9% (10yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | -45.5% | +51.4% (10yr)1 analysts |
Analysis
Recent growth has been strongest in EPS at +3.9% over three years. Forward estimates point to EBIT at +51.4% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
LifeStance Health Group, Inc.
NASDAQ:LFST
$3.44B
National HealthCare Corporation
AMEX:NHC
$3.02B
Acadia Healthcare Company, Inc.
NASDAQ:ACHC
$2.26B
Select Medical Holdings Corporation
NYSE:SEM
$2.05B
Pediatrix Medical Group, Inc.
NYSE:MD
$1.89B
Omnicell, Inc.
NASDAQ:OMCL
$1.73B
Aveanna Healthcare Holdings Inc.
NASDAQ:AVAH
$1.67B
Healthcare Services Group, Inc.
NASDAQ:HCSG
$1.56B
MannKind Corporation
NASDAQ:MNKD
$1.20B
U.S. Physical Therapy, Inc.
NYSE:USPH
$951.94M
Who manages ASTH?
Astrana Health, Inc. (ASTH) lists 12 active executives. The top listed executive is Boon Chen, Senior Vice President of Engineering.
Are ASTH insiders buying or selling?
Recent insider activity shows net selling of $24.84M.
Explore More
Continue the stock analysis
Jump to another research area for this company.